Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01054768 · ClinicalTrials.gov registry record · Phase 2
Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
A Phase 2 study, sponsored by UCSF Benioff Children's Hospital Oakland.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT01054768: Completed Phase 2 study, sponsored by UCSF Benioff Children's Hospital Oakland.
NCT01054768 is a Phase 2 study that has completed, run by UCSF Benioff Children's Hospital Oakland. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01054768, a Phase 2 study, has completed, sponsored by UCSF Benioff Children's Hospital Oakland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether alpha-lipoic acid and acetyl-L-carnitine will lower systemic inflammation in patients with Sickle Cell Disease by reducing oxidative stress, which will result in a decrease in the frequency of vaso-occlusive pain episodes and improve their quality of life.
Interventions
- DRUG Control
- DRUG alpha-lipoic acid and acetyl-L-carnitine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2009-08 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01054768
The ClinicalTrials.gov registry entry for NCT01054768 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCSF Benioff Children's Hospital Oakland, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT01054768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01054768 about?
NCT01054768 is a clinical study titled "Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease". The purpose of this study is to determine whether alpha-lipoic acid and acetyl-L-carnitine will lower systemic inflammation in patients with Sickle Cell Disease by reducing oxidative stress, which will result in a decrease in the frequency of vaso-occlusive pain episodes and improve their quality of...
What is the current status of trial NCT01054768?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2009-08. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01054768?
The interventions under investigation include: Control (DRUG), alpha-lipoic acid and acetyl-L-carnitine (DRUG).
Who is sponsoring clinical trial NCT01054768?
This trial is sponsored by UCSF Benioff Children's Hospital Oakland, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.